Background & Summary
====================

The NCI-60 Human Tumour Cell Lines Screen is an initiative started by the National Institutes of Health (NIH) in the late 1980s, focusing on the development of 59 human tumour cell lines for use as an *in vitro* drug screen model^[@b1]^ ([Table 1](#t1){ref-type="table"} (available online only)). These cell lines, derived from nine solid and blood malignancies, have shown great utility both in its original purpose for therapeutic screening as well as in basic cancer research (reviewed by Shoemaker *et al.*^[@b4]^). They have since been extensively characterized for various molecular features, including karyotypic complexity^[@b1]^, DNA fingerprinting^[@b2]^, gene expression microarray profiling^[@b5],[@b6]^, and human leukocyte antigen typing^[@b3]^. However, the small non-coding RNA (sncRNA) transcriptomes of the NCI-60 cell lines have yet to have been reported at the sequencing level.

The advent of next-generation sequencing has revealed the large proportion of non-coding genes in the human genome, and the relevance of these non-coding species in regulating the expression of both neighbouring and distant protein-coding genes. In the context of cancer, microRNAs (miRNAs) remain the best-studied non-coding RNA species, and have been implicated in all stages of cancer: initiation, progression, and response to therapy (reviewed by Hayes *et al.*^[@b7]^). Recent advances in the bioinformatic tools used for the discovery of small non-coding RNA have considerably expanded the number of known miRNA sequences^[@b8]^. Other types of sncRNA, including PIWI-interacting RNAs (piRNAs), small nuclear RNAs (snRNAs), and small nucleolar RNAs (snoRNAs) are emerging topics in cancer biology (reviewed by Ng *et al.* and Mannoor *et al.*^[@b9],[@b10]^). Beyond their functions in gene regulation, sncRNAs are attractive prognostic biomarkers due to their abundance and stability in various biofluids^[@b11]^.

We sequenced the sncRNA transcriptomes of the 59 cell lines in the panel ([Fig. 1](#f1){ref-type="fig"}). SncRNA profiles were generated using the OASIS analysis platform v2.0 (ref. [@b12]). For known sncRNA species (miRNAs, piRNAs, snoRNA, snRNA, and rRNA), high quality reads were mapped to the hg38 build of the human genome and quantified based on annotations containing their specific chromosomal locations. Detection of novel miRNAs was performed using well-established prediction algorithms that assess reads for miRNA folding characteristics, among other factors that indicate the probability that the tested sequence belongs to the miRNA family of sncRNAs^[@b13]^. In total, the genomic loci of 49,961 sncRNAs were examined. Using a detection threshold of greater than or equal to 5 reads across all tissues, we detected a total of 24,621 unique sncRNAs \[Data Citation 1\].

We then examined the genomic distribution of the detected sncRNAs across all tissue types ([Table 2](#t2){ref-type="table"},[Fig. 2](#f2){ref-type="fig"}). Notably, sncRNAs are expressed across all chromosomes in every tissue type assessed. SncRNA loci commonly expressed among all tissues may indicate their involvement in preserved biological or cancer-relevant processes, whereas differences in expression may denote tissue specificity.

We also examined the relative frequency of detection for each sncRNA species, both in the entire NCI-60 cell line panel and in lines grouped by organ type ([Fig. 3a](#f3){ref-type="fig"}). Beyond those annotated in miRBase (v.21), novel unannotated miRNAs were determined by integrating secondary structure formation potential with free energy scoring^[@b14]^. These novel miRNAs represent an increase of approximately 10% of total miRNAs expressed across all tissue types ([Fig. 3b](#f3){ref-type="fig"}), highlighting the constant expansion of the known non-coding transcriptome as sequencing technologies and bioinformatic tools advance. Consistent with the number of annotated loci in the human genome, piRNAs represent the largest proportion of sncRNA species expressed, followed by miRNA and snRNA ([Fig. 3a](#f3){ref-type="fig"}). Of note, an appreciable number of tissue-specific piRNA sequences across all tissues analyzed increased the relative fraction of piRNAs for all tissues expressed ([Fig. 3c,d](#f3){ref-type="fig"}). Thus, as parts of the small non-coding RNA transcriptome are significantly understudied, we provide this resource to the research community for studying sncRNA-related genetic and epigenetic regulation in cancer using the NCI-60 cell models.

Methods
=======

Cell line and sequencing information
------------------------------------

Cell line doubling times were obtained directly from the National Institutes of Health NCI (<https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm>), and year-of-origin information refers to data of first publication containing the cell line ([Table 1](#t1){ref-type="table"} (available online only)). Cell lines were obtained directly from the National Cancer Institute (NCI), were thawed and passaged twice precisely before total RNA was manually extracted using phenol-chloroform protocols from all cell lines using Trizol reagent (Invitrogen, CA, USA). 5,000 ng of extracted RNA per sample was used for sequencing input. Sequencing was performed in accordance with The Cancer Genome Atlas miRNA sequencing protocol (described by Chu *et al.*^[@b15]^). Briefly, after ligation to adaptors, 15 cycles of PCR was performed for amplification (98 °C-15 s, 62 °C-30 s and 72 °C-15 s), followed by 5 min at 72 °C. Small RNA exclusion was performed using gel extraction on a 3% MetaPhor Agarose gel (Lonza Inc., Basel, Switzerland), selecting species shorter that 200 nucleotides in order to enrich for targets optimized at 22 nucleotides in length, and was subsequently ethanol-precipitated. Library quality was confirmed by analysis on the Agilent Bioanalyzer DNA1000 chip (Agilent Technologies). Small non-coding RNA sequencing was performed on the Illumina HiSeq2500 platform at the Michael Smith Genome Sciences Centre at the BC Cancer Research Centre, with 8 multiplexed libraries per sequencing lane ([Table 3](#t3){ref-type="table"} (available online only), [Fig. 1](#f1){ref-type="fig"})^[@b15],[@b16]^. Data resulting from small non-coding RNA sequencing can be found on the *Sequence Read Archive* \[Data Citation 2\].

Pre-processing and small non-coding RNA species detection
---------------------------------------------------------

Small-RNA sequencing data was analyzed according to published protocols^[@b17]^. In order to extract information for the sncRNA species of interest, unaligned reads (in FASTQ format) were trimmed for adaptors (Cutadapt v1.7.1) and based on sequencing quality ('trim bases' from Partek Flow v6.0.17.0614) to reach a Phred quality score ≥20 ([Fig. 4a--d](#f4){ref-type="fig"}). FASTQ files were then aligned using the Spliced Transcripts Alignment to a Reference (STAR v2.4.1d) aligner to the human genome (hg38)^[@b18]^. Quantification algorithms (featureCounts v1.4.6 (ref. [@b19]) were applied using chromosomal location annotations for known miRNA (Mirbase v.21 (ref. [@b20]), piRNA (piRNAbank v.2 (ref. [@b21]), snoRNA (Ensembl v.84 (ref. [@b22]), and snRNA (Ensembl v.84 (ref. [@b22]) locations^[@b12]^. Detection of novel miRNA is performed using the miRDeep2 algorithm (v2.0.0.5), which considers the relative free energy of miRNAs and their random folding *P*-values^[@b13]^. Chromosomal position of expressed small RNAs was plotted against and hg38 karyotype obtained from UCSC Genome Browser ([Fig. 2](#f2){ref-type="fig"}). According to OASIS sncRNA software recommendation (v2.0), sncRNA species were considered expressed if the total reads across all samples considered summed to ≥5 reads^[@b12]^. Data resulting from species quantification can be found in Data Citation 1.

Normalization and quantification
--------------------------------

Raw reads were scaled/normalized using reads per kilobase exon per million mapped reads (RPKM) method^[@b23]^, and expression correlation matrices were created using Pearson scores with unsupervised hierarchal clustering performed using one-minus-Pearson correlation scores ([Fig. 5](#f5){ref-type="fig"}). For validation of sncRNA expression, we then correlated miRNA species present in two published microarray cohorts of the NCI-60 cell lines. For the 50 (of the 59) cell lines also present in the Sanger Cell Line Database^[@b24]^ (<http://www.cancerrxgene.org/translation/CellLine>), raw reads from each unique sequence were correlated with expression of the sequence previously detected by microarray by rank-normalized Spearman\`s correlations (Table 4 (available online only)), and performed a similar analysis against all cell lines present in the cohort described by Sokilde *et al.*^[@b5]^.

Data Records
============

Raw unaligned sequencing reads (in FASTQ file format) are available through the *Sequence Read Archive* (Data Citation 2). Raw sequencing file names (in FASTQ format) are listed in [Table 3](#t3){ref-type="table"} (available online only). A summary of raw sequencing reads for each detected small RNA species are available at through *Figshare* (Data Citation 1).

Technical Validation
====================

High-throughput sequencing allows for direct in-depth analyses of the human genome, recently revealing a critical role for the expression of the non-coding transcriptome in both genetic and epigenetic regulatory processes.

Sequencing quality control
--------------------------

We examined only high-confidence reads from miRNA sequencing. Samples were sequenced to an average depth of 22.34±0.14 (mean±s.d.; [Table 3](#t3){ref-type="table"} (available online only), [Fig. 4b](#f4){ref-type="fig"}). In order to assure only the calling of high-quality sequencing reads, we filtered detected reads to only to include Phred scores ≥20. On average, samples had a Phred score of 33.24±1.28 ([Table 3](#t3){ref-type="table"} (available online only), [Fig. 4c](#f4){ref-type="fig"}). Additionally, reads for each sample had an average percent GC content of 46.26±1.6% ([Table 3](#t3){ref-type="table"}) (available online only). Unsupervised hierarchical clustering and similarity (one-minus-Spearman correlation) of normalized reads revealed relative similarity of sncRNA expression profiles across all cell lines and tissue types analyzed ([Fig. 5](#f5){ref-type="fig"}).

miRNA detection validation
--------------------------

In order to validate the detection of the sncRNA species in these cell lines, we correlated the raw reads per miRNA detected with corresponding miRNA detected by microarray^[@b24],[@b25]^. This analysis was performed for the 50 NCI-60 cell lines present in the Sanger Cell Line miRNA Normalized Data from the Broad Institute (<http://www.broadinstitute.org/cgi-bin/cancer/datasets.cgi>; File name: Sanger_miR_data1.pn.cn.matlab2.res). Using Spearman's Rank-Order correlation, we analyzed the correlation of this RMA-normalized miRNA expression to reads obtained from sequencing this cell line panel. Expression of miRNAs in all lines analyzed correlated significantly between sequencing and microarray analysis ([Table 4](#t4){ref-type="table"} (available online only); *P*-values \<0.0001, r~mean~=0.67). Similarly, we correlated sequencing-detected miRNA expression against a complete NCI-60 microarray cohort described by Sokilde *et al.*^[@b5]^. In this study, profiling was performed on the LNA-enhanced mercury Dx 9.2 microarray platform, and data was log~2~-normalized after pre-processing ([Table 4](#t4){ref-type="table"}; *P*-value range \<0.0001--0.0647, r~mean~=0.28). Microarray data from multiple platforms was compared to sequencing data presented here in order to de-emphasize platform bias and illustrate the need for comprehensive profiling when considering small RNA expression^[@b26]^.
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![Experimental workflow.\
Graphical representation of experimental procedure used to extract, process, and analyze RNA from cell lines.](sdata2017157-f1){#f1}

![Genome-wide distribution of expressed small non-coding RNA by tissue type.\
Genomic position of sncRNAs detected (reads≥5) in each tissue type in reference to the hg38 chromosome build karyotype. From inner-most ring to outer: breast (red), CNS (magenta), colon (purple), leukemia (blue), melanoma (teal), lung (green), ovarian (yellow), prostate (orange), and renal (red).](sdata2017157-f2){#f2}

![sncRNA distribution by tissue type.\
(**a**) Relative fraction of sncRNA species detected per tissue type. (**b**) Average fraction of currently annotated (blue) and novel unannotated (red) miRNA per tissue type. (**c**) Relative fraction of tissue-specific unique sncRNA sequences detected per tissue type. (**d**) Fraction of tissue-specific unique sncRNA species.](sdata2017157-f3){#f3}

![Sequencing and mapping quality.\
(**a**) Phred quality score per sncRNA base position. (**b**) Genome-wide read depth (column) and genome coverage (line) per sample. (**c**) Fraction of sequencing reads per Phred score. (**d**) Percentage of total reads aligned (unique: green, unaligned: red).](sdata2017157-f4){#f4}
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###### NCI-60 cell line characteristics.

  **Tissue**     **Cell line**   **Subtype**                                 **Cell type of origin**   **Doubling time (hrs)**   **Year of origin**   **Culture conditions**
  -------------- --------------- ------------------------------------------- ------------------------- ------------------------- -------------------- ------------------------
  **BREAST**     BT-549          Ductal Carcinoma                            Epithelial                *53.9*                    1978                 RPMI-1640+10% FBS
                 HS-578T         Carcinoma                                   Epithelial                *53.8*                    1977                 DMEM+10% FBS
                 MCF-7           Adenocarcinoma                              Epithelial                *25.4*                    1973                 MEM+10% FBS
                 MDA-MB-231      Adenocarcinoma                              Epithelial                *41.9*                    1974                 L-15 Medium+10% FBS
                 T-47D           Ductal Carcinoma                            Epithelial                *45.5*                    1981                 DMEM+10% FBS
  **CNS**        SF-539          Gliblastoma multiforme                      Right Temporal Lobe       *35.4*                    1986                 MEM+10% FBS
                 SF-295          Glioblastoma                                Left Temporal Lobe        *29.5*                    1986                 RPMI-1640+10% FBS
                 SF-268          Highly Anaplastic Astrocytoma               Right Parietal Lobe       *33.1*                    1987                 RPMI-1640+10% FBS
                 U251            Glioblastoma                                Non-Epithelial (CNS)      *23.8*                    1978                 EMEM+10% FBS
                 SNB-75          Glioblastoma                                Non-Epithelial (CNS)      *62.8*                    1988                 RPMI-1640+10% FBS
                 SNB-19          Astrocytoma                                 Left parieto-occipital    *34.6*                    1980                 Ham\'s F10+10% FBS
  **COLON**      COLO 205        Dukes\' Type D, colorectal adenocarcinoma   Epithelial                *23.8*                    1975                 RPMI-1640+10% FBS
                 HCT-15          Colon adenocarcinoma                        Epithelial                *20.6*                    1979                 RPMI-1640+10% FBS
                 HCC2998         Colon adenocarcinoma                        Epithelial                *31.5*                    1988                 RPMI-1640+10% FBS
                 HCT-116         Colon adenocarcinoma                        Epithelial                *17.4*                    1981                 McCoy\'s 5a+10% FBS
                 HT-29           Colon adenocarcinoma                        Epithelial                *19.5*                    1964                 RPMI-1640+10% FBS
                 KM12            Colon adenocarcinoma                        Epithelial                *23.7*                    1988                 DMEM+10% FBS
                 SW-620          Dukes\' Type D, colorectal adenocarcinoma   Epithelial                *20.4*                    1977                 L15+10% FBS
  **LEUKEMIA**   CCRF-CEM        Acute lymphoblastic leukemia                T lymphoblast             *26.7*                    1964                 RPMI-1640+10% FBS
                 HL-60(TB)       Acutre promyelocytic leukemia               Promyeloblast             *28.6*                    1977                 IMDM+20% FBS
                 K-562           Chronic myelogenous leukemia                Lymphoblast               *19.6*                    1975                 IMDM+20% FBS
                 MOLT-4          Acute lymphoblastic leukemia                Lymphoblast               *27.9*                    1980                 RPMI-1640+10% FBS
                 RPMI 8226       Plasmacytoma; myeloma                       B Lymphocyte              *33.5*                    1966                 RPMI-1640+10% FBS
                 SR              Large cell immunoblastic lymphoma           Lymphoblast               *28.7*                    1983                 RPMI-1640+10% FBS
  **MELANOMA**   MALME-3M        Malignant melanoma                          Fibroblast                *46.2*                    1975                 IMDM+20% FBS
                 LOX-IMVI        Amelanotic melanoma                         Skin                      *20.5*                    1988                 RPMI-1640+10% FBS
                 M14             Malignant melanoma                          Skin                      *26.3*                    1976                 RPMI-1640+10% FBS
                 MDA-MB-435      Previously described as ductal carcinoma    Melanocyte                *25.8*                    1976                 L15+10% FBS
                 SK-MEL-28       Cutaneous melanoma                          Skin                      *35.1*                    1976                 DMEM+10% FBS
                 SK-MEL-5        Malignant melanoma                          Stellate                  *25.2*                    1977                 MEM+10% FBS
                 SK-MEL-2        Malignant melanoma                          Skin                      *45.5*                    1975                 MEM+10% FBS
                 UACC-257        Malignant melanoma                          Skin                      *38.5*                    1991                 RPMI-1640+10% FBS
                 UACC-62         Melanotic melanoma                          Skin                      *31.3*                    1991                 RPMI-1640+10% FBS
  **NSCLC**      A549            Adenocarcinoma                              Epithelial                **22.9**                  1972                 RPMI-1640+10% FBS
                 EKVX            Adenocarcinoma                              Epithelial                *43.6*                    1988                 RPMI-1640+10% FBS
                 HOP 92          Large cell carcinoma                        Epithelial                *79.5*                    1991                 RPMI-1640+10% FBS
                 HOP 62          Adenocarcinoma                              Epithelial                *39*                      1989                 RPMI-1640+10% FBS
                 NCI-H23         Adenocarcinoma                              Epithelial                **33.4**                  1980                 RPMI-1640+10% FBS
                 NCI-H322M       Small cell bronchioloalveolar carcinoma     Epithelial                *35.3*                    1991                 RPMI-1640+10% FBS
                 NCI-H226        Squamous cell carcinoma; mesothelioma       Epithelial                *61*                      1980                 RPMI-1640+10% FBS
                 NCI-H460        Carcinoma; large cell lung cancer           Epithelial                *17.8*                    1982                 RPMI-1640+10% FBS
                 NCI-H522        Adenocarcinoma                              Epithelial                *38.2*                    1985                 RPMI-1640+10% FBS
  **OVARIAN**    IGR-OV1         Ovarian endometrioid adenocarcinoma         Endometreoid              *31*                      1985                 RPMI-1640+10% FBS
                 NCI/ADR-RES     High Grade Ovarian Serous Adenocarcinoma    Epithelial                *34*                      1986                 RPMI-1640+20% FBS
                 OVCAR-3         Adenocarcinoma                              Epithelial                *34.7*                    1982                 RPMI-1640+10% FBS
                 OVCAR-8         High Grade Ovarian Serous Adenocarcinoma    Epithelial                *26.4*                    1984                 RPMI-1640+10% FBS
                 OVCAR-4         High Grade Ovarian Serous Adenocarcinoma    Epithelial                *41.4*                    1984                 RPMI-1640+10% FBS
                 OVCAR-5         High Grade Ovarian Serous Adenocarcinoma    Epithelial                *48.8*                    1984                 RPMI-1640+10% FBS
                 SK-OV-3         Adenocarcinoma                              Epithelial                *48.7*                    1973                 RPMI-1640+10% FBS
  **PROSTATE**   DU-145          Prostate carcinoma                          Epithelial                *32.3*                    1978                 MEM+10% FBS
                 PC-3            Adenocarcinoma                              Epithelial                *27.1*                    1980                 F-12K+10% FBS
  **RENAL**      A498            Carcinoma                                   Epithelial                *66.8*                    1977                 MEM+10% FBS
                 CAKI-1          Clear cell renal cell carcinoma             Epithelial                *39*                      1975                 McCoy\'s 5a+10% FBS
                 786-0           Renal cell adenocarcinoma                   Epithelial                *22.4*                    1976                 RPMI-1640+10% FBS
                 ACHN            Renal cell adenocarcinoma                   Epithelial                *27.5*                    1979                 MEM+10% FBS
                 RXF393          Renal cell carcinoma                        Epithelial                *62.9*                    1991                 RPMI-1640+10% FBS
                 SN12C           Renal cell carcinoma                        Epithelial                *29.5*                    1986                 DMEM+10% FBS
                 TK-10           Clear cell renal cell carcinoma             Epithelial                *51.3*                    1987                 RPMI-1640+10% FBS
                 UO-31           Renal cell carcinoma                        Epithelial                *41.7*                    1991                 DMEM+10% FBS

###### Average number of sncRNA species detected and sequencing coverage per tissue type.

                    **Number of sncRNA**   **Sequencing details**                                                                            
  ----------------- ---------------------- ------------------------ ----- -------- ----- ------- ----- ------------ ------- ------- -------- -------
  **Tissue type**   24,794                 2,509                    288   19,018   259   1,602   412   23,457,233   22.34   33.25   46.26%   28.94
  Breast            11,079                 1,905                    183   6,909    239   1,248   403   25,310,156   22.32   33.23   45.81%   25.36
  CNS               10,120                 1,793                    180   6,150    236   1,175   397   25,633,608   22.35   33.34   44.57%   45.08
  Colon             13,985                 1,977                    211   8,050    232   1,276   392   25,850,349   22.22   33.2    46.15%   22.97
  Leukemia          10,728                 1,841                    185   5,604    228   1,112   387   18,921,562   22.41   33.25   48.77%   20.23
  Melanoma          9,536                  1,830                    179   4,694    224   1,020   383   16,116,671   22.36   32.64   46.56%   28.45
  NSCLC             15,707                 2,051                    232   9,385    236   1,293   398   23,407,812   22.34   33.3    46.18%   22.8
  Ovarian           10,422                 1,916                    188   6,312    238   1,167   398   27,221,870   22.4    34.12   46.56%   41.49
  Prostate          6,167                  1,393                    121   2,589    216   771     344   35,637,053   22.3    33.54   44.44%   30.11
  Renal             14,532                 1,943                    209   8,549    234   1,288   396   23,949,373   22.3    33      45.99%   27.05

###### Sequencing quality metrics for sequenced cell line

  **Tissue**                **External ID**   **Sample name (.fastq)**   **Total reads**   **Total alignments**   **Aligned**   **Total unaligned**   **Unaligned**   **Total unique**   **Unique**   **Total non-unique**   **Non-unique**   **Coverage**   **Avg. coverage depth**   **Avg. length**   **Avg. quality**   **%GC**
  ------------------------ ----------------- --------------------------- ----------------- ---------------------- ------------- --------------------- --------------- ------------------ ------------ ---------------------- ---------------- -------------- ------------------------- ----------------- ------------------ ---------
  Breast                        BT-549        MX1381-C9C07ANXX-1-CACTGT  26,779,757        20,087,593             74.84%        6,738,932             25.16%          19,994,122         74.66%       46,703                 0.17%            0.62%          23.36                     22.33             33.02              47.70%
                                HS-578T       MX1383-C9C07ANXX-3-GGGGTT  24,961,809        20,875,168             83.42%        4,137,590             16.58%          20,773,358         83.22%       50,861                 0.20%            0.35%          41.95                     22.13             34.19              45.13%
                                 MCF-7        MX1384-C9C07ANXX-4-CTGGGT  43,741,142        32,170,069             73.27%        11,690,617            26.73%          31,931,263         73.00%       119,262                0.27%            0.81%          28.46                     22.27             33.55              42.37%
                              MDA-MB-231      MX1384-C9C07ANXX-4-GCCGGT  16,798,227        11,552,251             68.68%        5,261,551             31.32%          11,521,123         68.59%       15,553                 0.09%            0.43%          19.43                     22.45             33.25              46.01%
                                 T-47D        MX1387-C9C07ANXX-7-CTAAGG  14,269,847        9,004,918              63.04%        5,274,372             36.96%          8,986,041          62.97%       9,434                  0.07%            0.48%          13.58                     22.4              32.16              47.83%
  CNS                           SF-268        MX1386-C9C07ANXX-6-TAGTTG  35,537,775        32,273,096             90.47%        3,385,641             9.53%           32,031,463         90.13%       120,671                0.34%            0.28%          84.29                     22.35             34.68              46.13%
                                SF-295        MX1386-C9C07ANXX-6-CCGGTG  26,519,319        23,694,543             89.10%        2,890,215             10.90%          23,563,806         88.86%       65,298                 0.25%            0.24%          70.66                     22.39             34.43              42.31%
                                SF-539        MX1386-C9C07ANXX-6-ATCGTG  25,500,558        23,012,418             90.00%        2,549,670             10.00%          22,889,448         89.76%       61,440                 0.24%            0.25%          65.79                     22.25             34.49              46.43%
                                SNB-19        MX1387-C9C07ANXX-7-GCGTGG  32,717,872        21,567,743             65.75%        11,204,285            34.25%          21,459,531         65.59%       54,056                 0.17%            0.85%          18.3                      22.44             32.24              43.60%
                                SNB-75        MX1387-C9C07ANXX-7-CATGGG  12,680,815        7,882,308              62.10%        4,805,816             37.90%          7,867,693          62.04%       7,306                  0.06%            0.37%          15.13                     22.2              32.05              45.20%
                                 U251         MX1387-C9C07ANXX-7-ATTCCG  20,845,308        13,006,365             62.30%        7,858,915             37.70%          12,966,435         62.20%       19,958                 0.10%            0.58%          16.29                     22.47             32.17              43.76%
  Colon                        COLO 205       MX1381-C9C07ANXX-1-TCAAGT  18,351,752        13,907,298             75.66%        4,466,918             24.34%          13,862,401         75.54%       22,433                 0.12%            0.44%          22.77                     22.23             33.19              45.58%
                                HCC2998       MX1382-C9C07ANXX-2-GTAGCC  22,418,943        16,741,250             74.53%        5,710,380             25.47%          16,675,921         74.38%       32,642                 0.15%            0.88%          13.4                      21.83             32.83              47.12%
                                HCT-116       MX1382-C9C07ANXX-2-TACAAG  19,321,624        13,822,479             71.42%        5,521,561             28.58%          13,777,662         71.31%       22,401                 0.12%            0.54%          18.43                     22.23             33.06              46.02%
                                HCT-15        MX1382-C9C07ANXX-2-ATGTTT  22,372,577        15,816,346             70.57%        6,585,278             29.43%          15,758,281         70.44%       29,018                 0.13%            0.62%          18.15                     22.24             32.92              46.00%
                                 HT-29        MX1383-C9C07ANXX-3-CAAGTT  43,295,013        36,704,351             84.42%        6,746,834             15.58%          36,392,459         84.06%       155,720                0.36%            0.64%          40.79                     22.23             34.19              45.58%
                                 KM12         MX1383-C9C07ANXX-3-GTCCTT  21,097,776        17,022,531             80.52%        4,108,873             19.48%          16,955,321         80.37%       33,582                 0.16%            0.41%          29.68                     22.35             34.03              46.33%
                                SW-620        MX1387-C9C07ANXX-7-TTGCGG  34,094,755        22,349,352             65.38%        11,803,916            34.62%          22,232,420         65.21%       58,419                 0.17%            0.92%          17.57                     22.46             32.21              46.44%
  Leukemia                     CCRF-CEM       MX1381-C9C07ANXX-1-GATCTG  16,675,728        12,545,480             75.12%        4,148,470             24.88%          12,509,054         75.01%       18,204                 0.11%            0.40%          22.55                     22.48             33.4               49.05%
                               HL-60(TB)      MX1382-C9C07ANXX-2-TGCTTT  14,448,374        9,588,877              66.29%        4,870,207             33.71%          9,567,467          66.22%       10,700                 0.07%            0.51%          13.5                      22.12             32.72              49.74%
                                 K-562        MX1383-C9C07ANXX-3-TCGCTT  35,495,593        28,500,403             80.03%        7,089,711             19.97%          28,311,603         79.76%       94,279                 0.27%            0.60%          34.46                     22.43             34.08              48.92%
                                MOLT-4        MX1384-C9C07ANXX-4-GAGAGT  17,384,261        12,413,016             71.30%        4,989,141             28.70%          12,377,237         71.20%       17,883                 0.10%            0.49%          18.25                     22.49             33.61              48.27%
                               RPMI 8226      MX1385-C9C07ANXX-5-AGGAAT  17,460,565        14,241,842             81.43%        3,242,340             18.57%          14,194,637         81.30%       23,588                 0.14%            0.46%          22.37                     22.47             34.06              48.91%
                                  SR          MX1387-C9C07ANXX-7-CCACTC  12,064,850        6,751,739              55.92%        5,318,416             44.08%          6,741,131          55.87%       5,303                  0.04%            0.48%          10.23                     22.48             31.62              47.70%
  Melanoma                     LOX-IMVI       MX1383-C9C07ANXX-3-CCTATT  31,657,831        25,924,121             81.64%        5,812,011             18.36%          25,767,653         81.39%       78,167                 0.25%            0.47%          39.9                      22.38             34.1               45.79%
                                  M14         MX1383-C9C07ANXX-3-GTTTGT  16,456,810        13,115,289             79.57%        3,361,434             20.43%          13,075,479         79.45%       19,897                 0.12%            0.32%          29.6                      22.45             34.08              47.29%
                               MALME-3M       MX1383-C9C07ANXX-3-AGATGT  97,640            42,454                 43.48%        55,187                56.52%          42,452             43.48%       1                      0%               0.01%          4.85                      22.33             29.76              46.02%
                              MDA-MB-435      MX1384-C9C07ANXX-4-TATCGT  16,462,112        11,741,084             71.22%        4,736,983             28.78%          11,709,183         71.13%       15,946                 0.10%            0.50%          16.9                      22.36             33.4               47.73%
                               SK-MEL-2       MX1386-C9C07ANXX-6-TGAGTG  30,951,870        27,402,647             88.25%        3,636,213             11.75%          27,228,840         87.97%       86,817                 0.28%            0.32%          61.56                     22.51             34.52              46.50%
                               SK-MEL-28      MX1386-C9C07ANXX-6-CGCCTG  14,712,878        12,743,244             86.48%        1,988,450             13.52%          12,705,638         86.36%       18,790                 0.13%            0.22%          41.57                     22.26             34.24              46.57%
                               SK-MEL-5       MX1386-C9C07ANXX-6-GCCATG  12,394,333        10,855,860             87.48%        1,552,173             12.52%          10,828,474         87.37%       13,686                 0.11%            0.19%          41.26                     22.5              34.4               46.38%
                               UACC-257       MX1388-C9C07ANXX-8-AGCTAG  46,062            9,213                  20.00%        36,849                80.00%          9,213              20.00%       0                      0%               0%             2.13                      22.17             26.55              46.63%
                                UACC-62       MX1388-C9C07ANXX-8-GTATAG  22,270,501        15,834,593             70.97%        6,465,114             29.03%          15,776,225         70.84%       29,162                 0.13%            0.62%          18.26                     22.24             32.7               46.13%
  NSCLC                          A549         MX1381-C9C07ANXX-1-GCCTAA  24,542,337        18,533,593             75.35%        6,048,721             24.65%          18,453,696         75.19%       39,920                 0.16%            0.53%          25.18                     22.39             33.18              45.04%
                                 EKVX         MX1382-C9C07ANXX-2-AAGCTA  18,358,000        13,056,340             71.01%        5,321,501             28.99%          13,016,669         70.90%       19,830                 0.11%            0.46%          20.08                     22.13             32.99              45.71%
                                HOP 62        MX1382-C9C07ANXX-2-GCATTT  22,874,592        16,227,434             70.81%        6,678,209             29.19%          16,165,375         70.67%       31,008                 0.14%            0.58%          19.83                     22.18             32.86              45.15%
                                HOP 92        MX1382-C9C07ANXX-2-CGTACG  16,671,005        11,307,213             67.74%        5,378,661             32.26%          11,277,492         67.65%       14,852                 0.09%            0.49%          16.63                     22.16             32.7               45.80%
                               NCI-H226       MX1384-C9C07ANXX-4-TCTTCT  18,745,702        12,999,215             69.24%        5,766,399             30.76%          12,959,420         69.13%       19,883                 0.11%            0.52%          17.92                     22.38             33.28              47.25%
                                NCI-H23       MX1384-C9C07ANXX-4-CTATCT  19,234,429        13,677,426             71.00%        5,578,694             29.00%          13,634,066         70.88%       21,669                 0.11%            0.51%          19.47                     22.44             33.36              48.52%
                               NCI-H322M      MX1384-C9C07ANXX-4-GATGCT  40,017,514        30,184,128             75.16%        9,938,560             24.84%          29,974,031         74.90%       104,923                0.26%            0.95%          22.98                     22.47             33.58              45.76%
                               NCI-H460       MX1385-C9C07ANXX-5-AGCGCT  12,712,247        9,871,928              77.57%        2,851,889             22.43%          9,848,794          77.47%       11,564                 0.09%            0.32%          22.39                     22.38             33.72              47.50%
                               NCI-H522       MX1385-C9C07ANXX-5-CGGCCT  37,514,479        30,982,049             82.29%        6,643,642             17.71%          30,759,900         81.99%       110,937                0.30%            0.55%          40.76                     22.53             34.02              44.85%
  Ovarian                       IGR-OV1       MX1383-C9C07ANXX-3-AGTCTT  28,718,340        23,886,771             82.95%        4,897,725             17.05%          23,754,573         82.72%       66,042                 0.23%            0.42%          41.25                     22.41             34.16              46.10%
                              NCI/ADR-RES     MX1384-C9C07ANXX-4-ATCAGT  22,291,994        16,348,364             73.20%        5,974,630             26.80%          16,286,408         73.06%       30,956                 0.14%            0.54%          21.99                     22.37             33.49              47.02%
                                OVCAR-3       MX1385-C9C07ANXX-5-AATTAT  29,981,152        25,036,208             83.26%        5,017,926             16.74%          24,890,371         83.02%       72,855                 0.24%            0.46%          38.94                     22.41             34.16              47.68%
                                OVCAR-4       MX1385-C9C07ANXX-5-CCGTAT  28,168,179        22,957,608             81.29%        5,271,643             18.71%          22,835,575         81.07%       60,961                 0.22%            0.43%          38.31                     22.39             34.02              47.21%
                                OVCAR-5       MX1385-C9C07ANXX-5-TAGGAT  24,989,662        20,898,933             83.43%        4,141,256             16.57%          20,797,961         83.23%       50,445                 0.20%            0.40%          37.13                     22.3              34.22              45.64%
                                OVCAR-8       MX1385-C9C07ANXX-5-ATAGAT  21,340,411        17,484,019             81.76%        3,891,733             18.24%          17,413,389         81.60%       35,289                 0.17%            0.35%          36.62                     22.44             34.22              46.25%
                                SK-OV-3       MX1386-C9C07ANXX-6-AAAATG  35,063,352        31,836,638             90.46%        3,344,843             9.54%           31,600,666         90.12%       117,843                0.34%            0.30%          76.21                     22.49             34.54              46.04%
  Prostate                      DU-145        MX1382-C9C07ANXX-2-CTGATC  42,719,250        30,543,575             71.24%        12,284,018            28.76%          30,327,141         70.99%       108,091                0.25%            1.01%          21.68                     22.17             32.93              42.80%
                                 PC-3         MX1385-C9C07ANXX-5-GCTCAT  28,554,855        23,674,991             82.68%        4,944,659             17.32%          23,545,544         82.46%       64,652                 0.23%            0.44%          38.54                     22.42             34.15              46.08%
  Renal                          786-0        MX1381-C9C07ANXX-1-CGTGAT  28,239,458        21,417,620             75.65%        6,875,229             24.35%          21,310,920         75.47%       53,309                 0.19%            0.53%          28.79                     22.32             33.21              45.18%
                                 A498         MX1381-C9C07ANXX-1-ACATCG  23,983,341        18,160,244             75.56%        5,861,378             24.44%          18,083,724         75.40%       38,239                 0.16%            0.49%          26.57                     22.26             33.14              44.19%
                                 ACHN         MX1381-C9C07ANXX-1-TGGTCA  26,253,335        20,447,816             77.70%        5,854,225             22.30%          20,350,495         77.52%       48,615                 0.19%            0.50%          29.38                     22.42             33.4               44.66%
                                CAKI-1        MX1381-C9C07ANXX-1-ATTGGC  20,365,416        15,568,695             76.31%        4,825,051             23.69%          15,512,066         76.17%       28,299                 0.14%            0.38%          29.39                     22.37             33.42              44.53%
                                RXF393        MX1386-C9C07ANXX-6-CTTTTG  29,863,988        26,677,423             89.05%        3,269,280             10.95%          26,512,156         88.78%       82,552                 0.28%            0.34%          57.33                     22.42             34.42              48.85%
                                 SN12C        MX1387-C9C07ANXX-7-TGTTGG  23,377,833        15,428,844             65.88%        7,976,649             34.12%          15,373,563         65.76%       27,621                 0.12%            0.67%          16.45                     22.28             32.21              45.57%
                                 TK-10        MX1387-C9C07ANXX-7-TTCTCG  26,774,556        17,534,744             65.36%        9,275,498             34.64%          17,463,407         65.22%       35,651                 0.13%            1.16%          10.66                     21.92             31.69              49.55%
                                 UO-31        MX1388-C9C07ANXX-8-TCTGAG  12,737,055        8,368,476              65.64%        4,376,740             34.36%          8,352,163          65.57%       8,152                  0.06%            0.34%          17.82                     22.44             32.53              45.42%
  **MEAN**                  **23,457,233**         **18,073,055**        **74.34%**        **5,429,370**          **25.66%**    **17,982,756**        **74.18%**      **45,107**         **0.16%**    **0.49%**              **29**           **22.34**      **33.25**                 **46.26%**                           
  **Standard Deviation**     **9,294,225**          **7,957,399**        **11.69%**        **2,519,478**          **11.69%**    **7,888,112**         **11.63%**      **35,871**         **0.08%**    **0.22%**              **17**           **0.14**       **1.28**                  **1.64%**                            

###### Spearman correlation of sequenced NCI-60 cell lines to published miRNA microarray expression levels

                **Broad**    **Sokilde** ***et al.***                                         
  ------------- ----------- -------------------------- ---------- -------- ------------------ ----------
  786-0         0.7064            0.651--0.7543        \<0.0001   0.3252     0.1976--0.4421   \<0.0001
  A598          n/a                    n/a             n/a        0.2644     0.1327--0.3869   \<0.0001
  A549          0.6809            0.6218--0.7324       \<0.0001   0.1815    0.04619--0.3103   0.0071
  ACHN          0.6959            0.6389--0.7453       \<0.0001   0.27       0.1387--0.392    \<0.0001
  BT-549        n/a                    n/a             n/a        0.3202     0.1922--0.4376   \<0.0001
  CAKI-1        0.7004            0.6441--0.7492       \<0.0001   0.1604    0.02453--0.2905   0.0175
  CCRF-CEM      n/a                    n/a             n/a        0.1251    -0.01157--0.2571  0.0647
  COLO-205      0.6766            0.6169--0.7287       \<0.0001   0.2974     0.1677--0.4169   \<0.0001
  DU-145        0.726             0.6735--0.7711       \<0.0001   0.3293     0.2019--0.4457   \<0.0001
  EKVX          0.6248            0.558--0.6836        \<0.0001   0.2634     0.1317--0.386    \<0.0001
  HCC2998       0.6512            0.5879--0.7066       \<0.0001   0.3391     0.2125--0.4545   \<0.0001
  HCT-116       0.7019            0.6458--0.7505       \<0.0001   0.3393     0.2127--0.4547   \<0.0001
  HCT-15        0.7193            0.6658--0.7654       \<0.0001   0.2704     0.1391--0.3924   \<0.0001
  HL-60         0.6358            0.5704--0.6932       \<0.0001   0.2533     0.1211--0.3767   0.0002
  HOP-62        0.6899            0.632--0.7401        \<0.0001   0.2566     0.1245--0.3798   0.0001
  HOP-92        0.6576            0.5951--0.7121       \<0.0001   0.2288    0.09537--0.3542   0.0006
  HS-578-T      0.6283            0.5619--0.6867       \<0.0001   0.2857     0.1554--0.4063   \<0.0001
  HT-29         0.6956            0.6386--0.7451       \<0.0001   0.2875     0.1572--0.4079   \<0.0001
  IGR-OV1       0.6986            0.642--0.7476        \<0.0001   0.3065     0.1774--0.4251   \<0.0001
  K-562         n/a                    n/a             n/a        0.2657     0.1341--0.3881   \<0.0001
  KM12          n/a                    n/a             n/a        0.3265     0.1989--0.4432   \<0.0001
  LOX-IMVI      0.6699            0.6091--0.7228       \<0.0001   0.2637     0.132--0.3862    \<0.0001
  M14           0.6938            0.6365--0.7435       \<0.0001   0.2585     0.1265--0.3815   0.0001
  MALME-3M      0.5848            0.513--0.6485        \<0.0001   0.3069     0.1779--0.4256   \<0.0001
  MCF-7         0.7235            0.6707--0.769        \<0.0001   0.3271     0.1996--0.4438   \<0.0001
  MDA-MB-231    0.7125            0.658--0.7596        \<0.0001   0.1837    0.04847--0.3123   0.0064
  MDA-MB-435    0.7081            0.653--0.7558        \<0.0001   0.2907     0.1607--0.4109   \<0.0001
  MOLT-4        0.7034            0.6476--0.7518       \<0.0001   0.2809     0.1502--0.402    \<0.0001
  NCI/ADR-RES   n/a                    n/a             n/a        0.3046     0.1754--0.4234   \<0.0001
  NCI-H226      0.6901            0.6323--0.7403       \<0.0001   0.3613     0.2365--0.4743   \<0.0001
  NCI-H23       0.631              0.565--0.689        \<0.0001   0.2649     0.1332--0.3873   \<0.0001
  NCI-H322M     n/a                    n/a             n/a        0.3624     0.2378--0.4754   \<0.0001
  NCI-H460      0.6395            0.5746--0.6964       \<0.0001   0.2794     0.1486--0.4006   \<0.0001
  NCI-H522      0.7047            0.649--0.7529        \<0.0001   0.2856     0.1552--0.4062   \<0.0001
  OVCAR-3       0.6951            0.638--0.7446        \<0.0001   0.3629     0.2383--0.4758   \<0.0001
  OVCAR-4       0.6731            0.6128--0.7256       \<0.0001   0.3422     0.2158--0.4573   \<0.0001
  OVCAR-5       0.7101            0.6552--0.7575       \<0.0001   0.2952     0.1655--0.415    \<0.0001
  OVCAR-8       0.6613            0.5994--0.7154       \<0.0001   0.3407     0.2142--0.456    \<0.0001
  PC-3          0.6373            0.5721--0.6945       \<0.0001   0.2893     0.1592--0.4096   \<0.0001
  RPMI-8226     0.6704            0.6098--0.7233       \<0.0001   0.2641     0.1325--0.3866   \<0.0001
  RXF393        0.5656            0.4915--0.6316       \<0.0001   0.3085     0.1797--0.427    \<0.0001
  SF-268        0.6788            0.6193--0.7305       \<0.0001   0.2812     0.1505--0.4022   \<0.0001
  SF-295        0.6831            0.6243--0.7343       \<0.0001   0.2986     0.1691--0.418    \<0.0001
  SF-539        0.6623            0.6005--0.7162       \<0.0001   0.3037     0.1745--0.4227   \<0.0001
  SK-MEL-2      0.6294            0.5632--0.6876       \<0.0001   0.2851     0.1546--0.4057   \<0.0001
  SK-MEL-28     0.6765            0.6167--0.7286       \<0.0001   0.2867     0.1564--0.4072   \<0.0001
  SK-MEL-5      0.6095            0.5408--0.6702       \<0.0001   0.3681     0.2439--0.4804   \<0.0001
  SK-OV-3       0.658             0.5956--0.7125       \<0.0001   0.2613     0.1295--0.384    \<0.0001
  SN12C         0.7182            0.6645--0.7644       \<0.0001   0.321      0.193--0.4382    \<0.0001
  SNB-19        0.6126            0.5441--0.6729       \<0.0001   0.2332    0.09998--0.3583   0.0005
  SNB-75        n/a                    n/a             n/a        0.294      0.1642--0.4139   \<0.0001
  SR            n/a                    n/a             n/a        0.1599     0.02397--0.29    0.0179
  SW-620        0.7124            0.6578--0.7595       \<0.0001   0.3805     0.2575--0.4915   \<0.0001
  T-47D         0.6827            0.6238--0.7339       \<0.0001   0.3928     0.2709--0.5023   \<0.0001
  TK-10         0.7137            0.6593--0.7606       \<0.0001   0.1981    0.06341--0.3258   0.0032
  U-251         0.6242            0.5573--0.6831       \<0.0001   0.2862     0.1558--0.4067   \<0.0001
  UACC-257      0.4873            0.4049--0.5618       \<0.0001   0.2332    0.09994--0.3583   0.0005
  UACC-62       0.676             0.6161--0.7281       \<0.0001   0.3074     0.1785--0.426    \<0.0001
  UO-31         n/a                    n/a             n/a        0.2975     0.1672--0.4175   \<0.0001

[^1]: E.A.M. and V.D.M. were responsible for project design and manuscript construction. V.D.M. supervised data generation. E.A.M., A.P.S., K.W.N., V.D.M. and contributed to data analysis and manuscript preparation. N.S.F. contributed to data generation. K.L.B. and W.L.L. are the principal investigators who initiated this project. All authors contributed to the editing of the manuscript.
